UFP Technologies, Inc.

UFP Technologies, Inc.

UFPTNYSE / NASDAQHealthcareSmall cap

$290.85-$8.08 (-2.7%)

Last close · Data as of Nov 20, 2026

Market cap
$1.7B
P/E
25.4x
EV / EBITDA
16.8x
Revenue
$602.8M
Net margin
11.3%
ROCE
16.0%

+38.6% over the last year

UFP Technologies, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-0.2%
3M
-4.4%
6M
+29.4%
1Y
+38.6%
5Y
+318.8%

52-week range

Day change -$8.08 (-2.7%) from $299 to $291 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in UFPT, bought on each weekday since 2021.

News & filings

What UFP Technologies filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating profit was 9.4 times interest costs.

Concerns

No concern stands out for this company on the data on file.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

UFP Technologies, Inc., together with its subsidiaries, designs and manufactures solutions for medical devices, sterile packaging, and other engineered custom products in the United States.

Read moreShow less

UFP Technologies, Inc., together with its subsidiaries, designs and manufactures solutions for medical devices, sterile packaging, and other engineered custom products in the United States. The company provides protective drapes for robotic surgery, patient handling and comfort, advanced wound care, infection prevention, disposables for surgical and endoscopic procedures, packaging for medical devices, orthopedic implants, components for cardiac implants, dispenser coils for catheters, and biopharma drug manufacturing. It also offers equipment protection and packaging for firearms, unmanned aerial vehicles/drones, weapon systems, electronic devices communications equipment, and tools and repair kits; cushion and protective packaging; acoustic and thermal insulation components for automotive, aerospace, consumer, and industrial; filtration for small engines, air conditioners, humidifiers, refrigerators, electronic air cleaners, forced air appliances and industrial compressors; fluid management; and seals and gaskets for automotive manufacturing chemical processing, building and construction applications. In addition, the company provides uniform and tactical gear, such as backpack straps and padding, uniform knee and elbow pads, duty belts, holsters, and helmet padding and others; sports and leisure including custom helmet linings, athletic braces, and shoe insoles; and trim and structural components, consist of load floors, sunshades, package trays, back panel, and seat backs. The company serves the medical, aerospace and defence, automotive, consumer, electronics, and industrial markets. It markets and sells its products through a direct sales force. The company was founded in 1963 and is headquartered in Newburyport, Massachusetts.

Sector
Healthcare
Shares outstanding
7.7M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.7B
P/E
25.4x
P/B
4.1x
EV / EBITDA
16.8x
EV / Sales
3.1x
P/S
2.9x
52-week high
$334.84
52-week low
$185.45

Profitability

Operating margin
15.4%
Net margin
11.3%
EBITDA margin
18.5%
ROE
16.1%
ROCE
16.0%
ROA
10.4%
Asset turnover
0.92

Growth

Revenue
$602.8M
Revenue growth, 1Y
19.5%
Revenue CAGR, 3Y
19.4%
Net profit growth, 1Y
15.8%
Free cash flow
$79.0M

Solvency

Current ratio
2.68
Debt / Equity
0.36
Debt / Assets
0.24
CFO / Net profit
1.35
Cash / Market cap
1.2%

Where the revenue went

Of every $100 of FY2025 revenue, $11 was left as net income.

UFP Technologies, Inc. income statement flow, FY2025
UFP Technologies, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$432.4M
RevenueGross profit$170.4M
Gross profitOperating expenses$77.4M
Gross profitOperating income$93.0M
Operating incomePretax income$82.5M
Operating incomeInterest and other expense$10.5M
Pretax incomeTax and other$14.2M
Pretax incomeNet income$68.3M

Revenue and net profit

Revenue grew 19.5% in FY2025; net profit is the dashed line.

UFP Technologies, Inc. revenue and net profit by fiscal year
UFP Technologies, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$353.8M$41.8M
FY2023$400.1M$44.9M
FY2024$504.4M$59.0M
FY2025$602.8M$68.3M

Cash flows

FY2025: $91.9M from operations, $79.0M free after investment (dashed).

UFP Technologies, Inc. operating and free cash flow by fiscal year
UFP Technologies, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$17.7M$4.0M
FY2023$41.3M$30.8M
FY2024$66.6M$56.9M
FY2025$91.9M$79.0M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$602.8M+19.5%1Y
EBITDA
$111.5M+16.4%1Y
Net profit
$68.3M+15.8%1Y
Cash from operations
$91.9M+38.0%1Y
Free cash flow
$79.0M+38.7%1Y
Revenue CAGR, 3Y
19.4%
Net profit CAGR, 3Y
17.8%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$602.8M$111.5M$68.3M$79.0M16.1%+19.5%+15.8%

Monthly returns

Month-by-month returns of UFPT across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$655.1M
Liabilities$231.2M
Equity$423.9M
Paid-in capital$45.9M
Retained earnings$374.8M
Treasury stock$590.0k

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; UFPT highlighted.

P/E against peers

UFPT trades at 25.4x earnings against a peer median of -15.5x.

  1. UFP Technologies, Inc. (this company)25.4x

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Rapport Therapeutics, Inc., SELLAS Life Sciences Group, Inc., Biohaven Ltd., Sionna Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
UFP Technologies, Inc.UFPTthis company$1.7B25.4x4.1x16.1%16.8x
Rapport Therapeutics, Inc.RAPP$1.8B—-178.2x-23.0%—
Surgery Partners, Inc.SGRY$1.8B-23.0x1.0x-4.5%9.9x
SELLAS Life Sciences Group, Inc.SLS$1.8B-66.2x25.1x-37.9%-60.4x
Biohaven Ltd.BHVN$1.7B-2.3x33.0x-1418.8%-2.4x
Agios Pharmaceuticals, Inc.AGIO$1.7B-4.1x1.4x-34.6%-3.6x
Sionna Therapeutics, Inc.SION$1.7B-22.7x5.6x-24.5%-18.7x
Taysha Gene Therapies, Inc.TSHA$1.7B-15.5x6.9x-44.1%-13.4x
Novavax, Inc.NVAX$1.7B3.8x-13.1x-344.7%3.4x
Peer median—-15.5x3.5x-36.3%-3.6x

Year-to-date ROI

UFPT since 1 January, against earlier years.

Historical volatility

UFPT's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

UFP Technologies, Inc. operating margin by fiscal year
UFP Technologies, Inc. operating margin by fiscal year
DateOperating margin
FY202212.6%
FY202315.3%
FY202416.7%
FY202515.4%
LineFY2025
Cost of revenueCost Of Revenue$432.4M
Gross profitGross Profit$170.4M
Operating expensesOperating Expense$77.4M
Selling, general and administrativeSelling General And Administration$77.4M
Total expensesTotal Expenses$509.8M
Pretax incomePretax Income$82.5M

Learn while you research

Academy chapters picked for UFP Technologies, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →